Cyramza Indications/Uses

Gastric Cancer: Ramucirumab (Cyramza), in combination with paclitaxel, is indicated for the treatment of adult patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy (see Pharmacology: Pharmacodynamics under Actions).
Ramucirumab (Cyramza) monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate (see Pharmacology: Pharmacodynamics under Actions).
Colorectal cancer: Ramucirumab (Cyramza), in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
Non-small cell lung cancer: Ramucirumab (Cyramza) in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations (see Pharmacology: Pharmacodynamics under Actions).
Ramucirumab (Cyramza), in combination with docetaxel, is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.
Hepatocellular carcinoma: Ramucirumab (Cyramza) monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥400 ng/mL and who have been previously treated with sorafenib.